News & Media

Stay up to date with our activities by browsing our press releases and company presentations below.

Press Material


Patric Stenberg, CEO

+46 (0)733 83 66 70 

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate GS-248 is currently under evaluation in a phase 2 study.